Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Appointed director
EAGLE PHARMACEUTICALS, INC. (EGRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/27/2023 8-K Quarterly results
08/17/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Eagle Pharmaceuticals Reiterates 2023 Adjusted non-GAAP EBITDA and Adjusted non-GAAP EPS 1 Guidance -- FY 2023 Adjusted non-GAAP EBITDA expected to be $78.0 - $84.0 million 1 -- -- FY 2023 Adjusted non-GAAP earnings per share expected to be $4.40 - $4.70 1 -- -- Reflects strength of Eagle’ s business and product pipeline; Company poised for sustained long-term growth – WOODCLIFF LAKE, N.J. — August 17, 2023 — Eagle Pharmaceuticals, Inc. today reiterated its previously issued guidance for the 2023 fiscal year. Full-year 2023 Adjusted non-GAAP EBITDA is expected to range from $78.0 to $84.0 million and Adjusted non-GAAP earnings per share is expected to range from $4.40 to $4.70. “Based on the strength of our business and product pipeline, we are reiterating our recently increased guidance ..."
08/08/2023 8-K Quarterly results
Docs: "Eagle Pharmaceuticals Reports Second Quarter 2023 Results · Total revenue for Q2 2023 was $64.6 million · Q2 2023 net income was $0.39 per basic and diluted share and adjusted non-GAAP net income 1 was $1.18 per basic and diluted share · Q2 2023 net income was $5.2 million · Q2 2023 adjusted non-GAAP EBITDA 1 was $20.7 million · Gross margin was 74% for the first half of 2023, up from 73% for the first half of 2022 · Adjusted non-GAAP gross margin 1 was 83% for the first half of 2023, up from 74% for the first half of 2022 · Gross profit in its oncology business was $41.9 million in the second quarter of 2023 compared with $38.7 million in the prior year period, representing gross margin of 80% and 72%, respectively · Adjusted non-GAA..."
07/31/2023 8-K Quarterly results
07/24/2023 8-K Quarterly results
07/18/2023 8-K Regulation FD Disclosure  Interactive Data
06/30/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/09/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
06/06/2023 8-K Investor presentation
Docs: "2016 2017 2018 2019 2020 2021 2022 2023E"
05/09/2023 8-K Quarterly results
Docs: "Eagle Pharmaceuticals Reports First Quarter 2023 Results · Total revenue for Q1 2023 was $66.3 million, compared to $115.9 million in Q1 2022 · Q1 2023 net income was $0.44 per basic and diluted share and adjusted non-GAAP net income 1 was $1.27 per basic and $1.26 per diluted share · Q1 2023 adjusted non-GAAP EBITDA of $22.3 million · Q1 2023 net sales of PEMFEXY totaled $22.9 million; Eagle estimates that it has an approximate 15% share in commercial pemetrexed market for the second quarter of 2023 to date 2 · BENDEKA ®3 and BELRAPZO ®4 - both ready-to-dilute products — combined maintained approximately 89% share of the bendamustine U.S. market for the first quarter of 2023 compared to approximately 90% historically 5 · Company reaffirms full yea..."
05/01/2023 8-K Quarterly results
03/13/2023 8-K Quarterly results
Docs: "Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results · Q4 2022 net income was $0.63 per basic and $0.62 per diluted share and adjusted non-GAAP net income was $1.11 per basic and $1.10 per diluted share 1 · Total revenue for Q4 2022 was $60.7 million, compared to $42.3 million in Q4 2021 · FY 2022 net income was $2.76 per basic and $2.73 per diluted share and adjusted non-GAAP net income was $7.87 per basic and $7.79 per diluted share 1 · FY 2022 revenue was $316.6 million compared to $171.5 million in FY 2021 · FY 2022 net sales of PEMFEXY ® totaled $67.5 million, and were $12.1 million in Q4 2022, representing a 6% U.S. market share in community oncology at the end of Q4 2022; already captured a 10% share through February 2023; antici..."
01/10/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Eagle Pharmaceuticals Provides Business Update and Guidance for 2023 Woodcliff Lake, N.J. – January 10, 2023 -- Eagle Pharmaceuticals, Inc. today provided a business update and guidance for 2023. Highlights: · During the 12 months ended September 30, 2022, Eagle recorded net income of $21.3 million or $1.63 per diluted share and adjusted EBITDA of $125.6 million and non-GAAP earnings per diluted share of $7.54, a significant increase from 2021. 1 · Eagle exited 2022 with an approximate 6% 2 share of the commercial segment of the pemetrexed market for its PEMFEXY ® product, equating to approximately $8 million per quarter in revenue 3 , and anticipates doubling its share by end of Q1 2023. The Company bought down future royalties on PEMFEXY profits in exchange for one-time pa..."
01/10/2023 8-K/A Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "2016 2017 2018 2019 2020 2021 LTM 9.30.22 2023E"
01/09/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "2016 2017 2018 2019 2020 2021 LTM 9.30.22 2023E"
12/19/2022 8-K Quarterly results
12/14/2022 8-K Quarterly results
12/12/2022 8-K Quarterly results
12/09/2022 8-K Quarterly results
12/06/2022 8-K Quarterly results
11/14/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Eagle Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Adjunct Treatment of Severe Community-Acquired Bacterial Pneumonia"
11/09/2022 8-K/A Quarterly results
11/07/2022 8-K Quarterly results
Docs: "Eagle Pharmaceuticals Reports Third Quarter 2022 Results · Q3 2022 net loss was $ per basic and diluted share and adjusted non-GAAP net income was $1.13 per basic and $1.12 per diluted share 1 · Total revenue for Q3 2022 was $65.9 million, compared to $39.9 million in Q3 2021 · Nine-month 2022 net income was $2.41 per basic and $2.38 per diluted share · Nine-month 2022 adjusted non-GAAP earnings per diluted share 1 more than doubled to $6.69 from full year 2021 adjusted non-GAAP earnings per diluted share, outperforming any full year in the Company’ s history · Nine-month 2022 revenue of $255.9 million exceeds full year 2021 revenue of $171.5 million · Nine-month 2022 net sales of vasopressin and PEMFEXY combined totaled $114.9 million · BEN..."
11/02/2022 8-K Quarterly results
10/12/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Eagle Pharmaceuticals Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Treatment of Severe Community-Acquired Bacterial Pneumonia -- Company plans to commence an adequately powered Phase 2 study with approximately 276 patients with severe community-acquired pneumonia at 120 sites worldwide with patient enrollment expected as early as the beginning of 2023 -- -- Interim results expected approximately one year after patient enrollment begins -- -- CAL02 is being developed as an add-on to the clinically indicated antibiotic treatment and potentially offers unique therapeutic benefits to critically ill patients, including immediate decrease in inflammatory biomarkers, ..."
10/03/2022 8-K Quarterly results
09/27/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Eagle Pharmaceuticals and Enalare Therapeutics Announce Additional Award Worth Up to $50 Million from BARDA to Advance an Intramuscular Formulation of ENA-001"
08/25/2022 8-K/A Financial Statements and Exhibits  Interactive Data
Docs: "CONSENT OF INDEPENDENT AUDITORS",
"Report of Independent Auditors",
"UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Introduction The following unaudited pro forma condensed combined financial information , which includes the unaudited pro forma combined statement of operations for the six months ended June 30, 2022 and for the year ended December 31, 2021 , has been prepared on the basis set out in the notes below to illustrate the effect of the transaction. On June 9, 2022, Eagle Pharmaceuticals, Inc. completed the acquisition of Acacia Pharma Group plc , pursuant to the terms of a Scheme Document relating to the Acquisition published by Acacia on April 27, 2022 . In connection with the consummation of the Acquisition each Acacia shareholder became entitled to receive €0.68 in cash and 0.0049 shares of common stock of the Company for eac..."
08/18/2022 8-K Quarterly results
08/09/2022 8-K Quarterly results
08/04/2022 8-K/A Submission of Matters to a Vote of Security Holders  Interactive Data
08/01/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
07/18/2022 8-K Quarterly results
07/18/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy